XML 89 R35.htm IDEA: XBRL DOCUMENT
v3.20.4

Revenues (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Revenue from Contract with Customer [Abstract] |
Revenue by product | Revenues by product are summarized as follows:
|  | For the Years Ended December 31,
|  | 2020 |  | 2019 |  | 2018
(In millions) |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fumarate* |  | $ | 2,742.0 |  |  | $ | 1,163.4 |  |  | $ | 3,905.4 |  |  | $ | 3,312.0 |  |  | $ | 1,126.2 |  |  | $ | 4,438.2 |  |  | $ | 3,253.2 |  |  | $ | 1,020.9 |  |  | $ | 4,274.1 |
Interferon** |  | 1,273.5 |  |  | 604.0 |  |  | 1,877.5 |  |  | 1,426.6 |  |  | 675.2 |  |  | 2,101.8 |  |  | 1,668.3 |  |  | 694.7 |  |  | 2,363.0 |
TYSABRI |  | 1,096.8 |  |  | 849.3 |  |  | 1,946.1 |  |  | 1,041.8 |  |  | 850.4 |  |  | 1,892.2 |  |  | 1,025.0 |  |  | 839.0 |  |  | 1,864.0 |
FAMPYRA |  | — |  |  | 103.1 |  |  | 103.1 |  |  | — |  |  | 97.1 |  |  | 97.1 |  |  | — |  |  | 92.7 |  |  | 92.7 |
ZINBRYTA |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1.4 |  |  | 1.4 |
Subtotal: MS |  | 5,112.3 |  |  | 2,719.8 |  |  | 7,832.1 |  |  | 5,780.4 |  |  | 2,748.9 |  |  | 8,529.3 |  |  | 5,946.5 |  |  | 2,648.7 |  |  | 8,595.2 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA |  | 787.8 |  |  | 1,264.3 |  |  | 2,052.1 |  |  | 933.4 |  |  | 1,163.6 |  |  | 2,097.0 |  |  | 854.0 |  |  | 870.2 |  |  | 1,724.2 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
BENEPALI |  | — |  |  | 481.6 |  |  | 481.6 |  |  | — |  |  | 486.2 |  |  | 486.2 |  |  | — |  |  | 485.2 |  |  | 485.2 |
IMRALDI |  | — |  |  | 216.3 |  |  | 216.3 |  |  | — |  |  | 184.0 |  |  | 184.0 |  |  | — |  |  | 16.7 |  |  | 16.7 |
FLIXABI |  | — |  |  | 97.9 |  |  | 97.9 |  |  | — |  |  | 68.1 |  |  | 68.1 |  |  | — |  |  | 43.2 |  |  | 43.2 |
Subtotal: Biosimilars |  | — |  |  | 795.8 |  |  | 795.8 |  |  | — |  |  | 738.3 |  |  | 738.3 |  |  | — |  |  | 545.1 |  |  | 545.1 |
Other: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM |  | — |  |  | 12.2 |  |  | 12.2 |  |  | — |  |  | 15.2 |  |  | 15.2 |  |  | — |  |  | 22.3 |  |  | 22.3 |
Total product revenues |  | $ | 5,900.1 |  |  | $ | 4,792.1 |  |  | $ | 10,692.2 |  |  | $ | 6,713.8 |  |  | $ | 4,666.0 |  |  | $ | 11,379.8 |  |  | $ | 6,800.5 |  |  | $ | 4,086.3 |  |  | $ | 10,886.8 |
*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019. **Interferon includes AVONEX and PLEGRIDY.
Analysis of change in reserves | An analysis of the change in reserves for discounts and allowances is summarized as follows:
|  | December 31, 2020
(In millions) |  | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Beginning balance |  | $ | 131.1 |  |  | $ | 1,027.3 |  |  | $ | 40.5 |  |  | $ | 1,198.9 |
Current provisions relating to sales in current year |  | 774.7 |  |  | 3,308.8 |  |  | 19.0 |  |  | 4,102.5 |
Adjustments relating to prior years |  | (1.0) |  |  | (54.0) |  |  | 1.3 |  |  | (53.7) |
Payments/returns relating to sales in current year |  | (635.1) |  |  | (2,426.1) |  |  | — |  |  | (3,061.2) |
Payments/returns relating to sales in prior years |  | (128.3) |  |  | (763.0) |  |  | (19.2) |  |  | (910.5) |
Ending balance |  | $ | 141.4 |  |  | $ | 1,093.0 |  |  | $ | 41.6 |  |  | $ | 1,276.0 |
|  | December 31, 2019
(In millions) |  | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Beginning balance |  | $ | 127.8 |  |  | $ | 888.8 |  |  | $ | 34.7 |  |  | $ | 1,051.3 |
Current provisions relating to sales in current year |  | 666.2 |  |  | 3,011.5 |  |  | 20.9 |  |  | 3,698.6 |
Adjustments relating to prior years |  | 0.3 |  |  | (54.1) |  |  | 5.5 |  |  | (48.3) |
Payments/returns relating to sales in current year |  | (535.5) |  |  | (2,242.9) |  |  | (0.2) |  |  | (2,778.6) |
Payments/returns relating to sales in prior years |  | (127.7) |  |  | (576.0) |  |  | (20.4) |  |  | (724.1) |
Ending balance |  | $ | 131.1 |  |  | $ | 1,027.3 |  |  | $ | 40.5 |  |  | $ | 1,198.9 |
|  | December 31, 2018
(In millions) |  | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Beginning balance |  | $ | 109.6 |  |  | $ | 606.0 |  |  | $ | 46.0 |  |  | $ | 761.6 |
Current provisions relating to sales in current year |  | 679.3 |  |  | 2,686.7 |  |  | 23.1 |  |  | 3,389.1 |
Adjustments relating to prior years |  | (0.3) |  |  | (10.0) |  |  | (1.8) |  |  | (12.1) |
Payments/returns relating to sales in current year |  | (551.7) |  |  | (1,887.6) |  |  | (1.1) |  |  | (2,440.4) |
Payments/returns relating to sales in prior years |  | (109.1) |  |  | (506.3) |  |  | (31.5) |  |  | (646.9) |
Ending balance |  | $ | 127.8 |  |  | $ | 888.8 |  |  | $ | 34.7 |  |  | $ | 1,051.3 |
Total reserves included in consolidated balance sheet | The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:
|  | As of December 31,
(In millions) |  | 2020 |  | 2019
Reduction of accounts receivable |  | $ | 195.4 |  |  | $ | 197.8 |
Component of accrued expenses and other |  | 1,080.6 |  |  | 1,001.1 |
Total revenue-related reserves |  | $ | 1,276.0 |  |  | $ | 1,198.9 |
Revenues from anti-CD20 therapeutic programs | Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
|  | For the Years Ended December 31,
(In millions) |  | 2020 |  | 2019 |  | 2018
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA |  | $ | 1,080.2 |  |  | $ | 1,542.4 |  |  | $ | 1,431.9 |
Other revenues from anti-CD20 therapeutic programs |  | 897.6 |  |  | 748.0 |  |  | 548.3 |
Total revenues from anti-CD20 therapeutic programs |  | $ | 1,977.8 |  |  | $ | 2,290.4 |  |  | $ | 1,980.2 |
Revenues from anti-CD20 therapeutic programs are summarized as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2020 |  | 2019 |  | 2018
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses |  | $ | 1,080.2 |  |  | $ | 1,542.4 |  |  | $ | 1,431.9 |
Other revenues from anti-CD20 therapeutic programs |  | 897.6 |  |  | 748.0 |  |  | 548.3 |
Total revenues from anti-CD20 therapeutic programs |  | $ | 1,977.8 |  |  | $ | 2,290.4 |  |  | $ | 1,980.2 |
Other revenues | Other revenues are summarized as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2020 |  | 2019 |  | 2018
Revenues from collaborative and other relationships: |  |  |  |  |  |
Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis |  | $ | 20.9 |  |  | $ | 106.2 |  |  | $ | 96.4 |
Other revenues from collaborative and other relationships |  | 0.7 |  |  | — |  |  | (8.6) |
Other royalty and corporate revenues: |  |  |  |  |  |
Royalty |  | 33.9 |  |  | 17.0 |  |  | 38.7 |
Other corporate |  | 719.1 |  |  | 584.5 |  |  | 459.4 |
Total other revenues |  | $ | 774.6 |  |  | $ | 707.7 |  |  | $ | 585.9 |

X
- Definition Analysis of amount of and change in product revenue reserves. + References No definition available. + Details
Name: | biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other revenues [Table Text Block] + References No definition available. + Details
Name: | biib_OtherrevenuesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of total product revenue reserves included in consolidated balance sheets. + References No definition available. + Details
Name: | biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration